Objectif
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be implemented by a multidisciplinary team that combines some of Europe's leading academic TB researchers with two major pharmaceutical companies and four SMEs, all strongly committed to the discovery of anti-infective agents. MM4TB will use a tripartite screening strategy to discover new hits in libraries of natural products and synthetic compounds, while concentrating on both classical and innovative targets that have been pharmacologically validated. Whole cell screens will be conducted against Mycobacterium tuberculosis using in vitro and ex vivo models for active growth, latency and intracellular infection. Hits that are positive in two or more of these models will then be used for target identification using functional genomics technologies including whole genome sequencing and genetic complementation of resistant mutants, yeast three hybrid, click chemistry and proteomics. Targets thus selected will enter assay development, structure determination, fragment-based and rational drug design programs; functionally related targets will be found using metabolic pathway reconstruction. Innovative techniques, based on microfluidics and array platforms, will be used for hit ranking, determining rates of cidality and confirming mechanism of action. Medicinal chemistry will convert leads to molecules with drug-like properties for evaluation of efficacy in different animal models and late preclinical testing.
Champ scientifique
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomics
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesclinical medicinepneumologytuberculosis
- natural sciencesbiological sciencesgeneticsgenomes
Appel à propositions
FP7-HEALTH-2010-single-stage
Voir d’autres projets de cet appel
Régime de financement
CP-IP - Large-scale integrating projectCoordinateur
1015 Lausanne
Suisse
Voir sur la carte
Participants (26)
Participation terminée
560024 BANGALORE
Voir sur la carte
751 05 Uppsala
Voir sur la carte
27100 Pavia
Voir sur la carte
CB2 1TN Cambridge
Voir sur la carte
Participation terminée
E1 4NS London
Voir sur la carte
75724 Paris
Voir sur la carte
119071 MOSCOW
Voir sur la carte
35122 Padova
Voir sur la carte
814 99 Bratislava
Voir sur la carte
8200 VESZPREM
Voir sur la carte
NR4 7UH Norwich
Voir sur la carte
560012 Bangalore
Voir sur la carte
560066 BANGALORE
Voir sur la carte
13100 Vercelli
Voir sur la carte
94010 BURLINGAME CA
Voir sur la carte
48940 Leioa
Voir sur la carte
41126 Modena
Voir sur la carte
50009 Zaragoza
Voir sur la carte
8092 Zuerich
Voir sur la carte
07749 JENA
Voir sur la carte
94250 GENTILLY
Voir sur la carte
7701 Rondebosch
Voir sur la carte
Participation terminée
1025 Saint Sulpice
Voir sur la carte
75654 Paris
Voir sur la carte
1015 Lausanne
Voir sur la carte
65929 Frankfurt Am Main
Voir sur la carte